Protalix BioTherapeutics, Chiesi Global Get FDA Approval for Elfabrio
By Chris Wack
Protalix BioTherapeutics and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, said Wednesday that the U.S. Food and Drug Administration has approved Elfabrio pegunigalsidase alfa-iwxj in the U.S. for the treatment of adult patients with Fabry disease.
Elfabrio is a PEGylated enzyme replacement therapy.
The companies said the safety, tolerability and efficacy of Elfabrio has been studied in a comprehensive clinical development program in more than 140 patients with up to 7 and one-half years of follow up treatment. Elfabrio was generally well-tolerated with the majority of adverse events being mild or moderate in severity.
In clinical trials, 20 Elfabrio-treated patients experienced hypersensitivity reactions. Four Elfabrio-treated patients experienced anaphylaxis reactions that occurred within 5 to 40 minutes of the start of the initial infusion.
Protalix BioTherapeutics shares were up 14% to $3.32 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 10, 2023 06:38 ET (10:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth